FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2023773454> ?p ?o ?g. }

• W2023773454 endingPage "650" @default.
• W2023773454 startingPage "642" @default.
• W2023773454 abstract "Background In patients with psoriasis and inadequate response (IR) to tumor necrosis factor-α antagonist treatment, the incremental benefit of switching to another tumor necrosis factor-α antagonist is unknown. Objective We sought to evaluate the clinical response to an etanercept-to-infliximab switch in patients with psoriasis and IR to etanercept. Methods Adults with moderate-to-severe plaque psoriasis and IR to etanercept (≥4 months) were eligible for this open-label study (called PSUNRISE). Patients had a Physician Global Assessment (PGA) score of at least 2 (mild) on a 5-point scale with etanercept, with or without concomitant oral systemic methotrexate or cyclosporine at baseline and during the study. Patients received intravenous infusions of infliximab 5 mg/kg at weeks 0, 2, 6, 14, and 22. PGA was used to evaluate efficacy at week 10 (primary end point) and week 26 (durability). Safety was evaluated through the end of the study. Results Of 215 patients, only 10 received concomitant immunomodulators. At week 10, 65.4% of patients (138 of 211; 95% confidence interval 58.6%-71.8%) achieved a PGA score of clear (0) or minimal (1) (primary end point). This response was durable through week 26, at which time 61.3% (122 of 199; 95% confidence interval 54.2%-68.1%) achieved a PGA score of clear (0) or minimal (1). There were no unexpected side effects or safety concerns. Limitations This was an open-label, 26-week study; an incremental change of 1 PGA point, even mild to minimal, was considered clinically significant, as most psoriasis practitioners seek to achieve minimal psoriasis or clear skin. Conclusion After switching to infliximab, a substantial proportion of patients with psoriasis and IR to etanercept experienced rapid and durable improvement. In patients with psoriasis and inadequate response (IR) to tumor necrosis factor-α antagonist treatment, the incremental benefit of switching to another tumor necrosis factor-α antagonist is unknown. We sought to evaluate the clinical response to an etanercept-to-infliximab switch in patients with psoriasis and IR to etanercept. Adults with moderate-to-severe plaque psoriasis and IR to etanercept (≥4 months) were eligible for this open-label study (called PSUNRISE). Patients had a Physician Global Assessment (PGA) score of at least 2 (mild) on a 5-point scale with etanercept, with or without concomitant oral systemic methotrexate or cyclosporine at baseline and during the study. Patients received intravenous infusions of infliximab 5 mg/kg at weeks 0, 2, 6, 14, and 22. PGA was used to evaluate efficacy at week 10 (primary end point) and week 26 (durability). Safety was evaluated through the end of the study. Of 215 patients, only 10 received concomitant immunomodulators. At week 10, 65.4% of patients (138 of 211; 95% confidence interval 58.6%-71.8%) achieved a PGA score of clear (0) or minimal (1) (primary end point). This response was durable through week 26, at which time 61.3% (122 of 199; 95% confidence interval 54.2%-68.1%) achieved a PGA score of clear (0) or minimal (1). There were no unexpected side effects or safety concerns. This was an open-label, 26-week study; an incremental change of 1 PGA point, even mild to minimal, was considered clinically significant, as most psoriasis practitioners seek to achieve minimal psoriasis or clear skin. After switching to infliximab, a substantial proportion of patients with psoriasis and IR to etanercept experienced rapid and durable improvement." @default.
• W2023773454 created "2016-06-24" @default.
• W2023773454 creator A5012920754 @default.
• W2023773454 creator A5018964407 @default.
• W2023773454 creator A5031806804 @default.
• W2023773454 creator A5038028069 @default.
• W2023773454 creator A5049859852 @default.
• W2023773454 creator A5058395343 @default.
• W2023773454 creator A5060819284 @default.
• W2023773454 creator A5061557806 @default.
• W2023773454 creator A5074434801 @default.
• W2023773454 creator A5080223253 @default.
• W2023773454 creator A5080237247 @default.
• W2023773454 date "2012-10-01" @default.
• W2023773454 modified "2023-09-26" @default.
• W2023773454 title "The efficacy and safety of infliximab in patients with plaque psoriasis who had an inadequate response to etanercept: Results of a prospective, multicenter, open-label study" @default.
• W2023773454 cites W123093596 @default.
• W2023773454 cites W1962011113 @default.
• W2023773454 cites W1971708477 @default.
• W2023773454 cites W1975463338 @default.
• W2023773454 cites W1987784314 @default.
• W2023773454 cites W1997106678 @default.
• W2023773454 cites W2013361256 @default.
• W2023773454 cites W2028656318 @default.
• W2023773454 cites W2029471930 @default.
• W2023773454 cites W2049017267 @default.
• W2023773454 cites W2060132373 @default.
• W2023773454 cites W2067327580 @default.
• W2023773454 cites W2069350424 @default.
• W2023773454 cites W2073601928 @default.
• W2023773454 cites W2075382650 @default.
• W2023773454 cites W2091442391 @default.
• W2023773454 cites W2096991001 @default.
• W2023773454 cites W2108779144 @default.
• W2023773454 cites W2109304329 @default.
• W2023773454 cites W2122265491 @default.
• W2023773454 cites W2146843653 @default.
• W2023773454 cites W2151991135 @default.
• W2023773454 cites W2161344815 @default.
• W2023773454 cites W2171309002 @default.
• W2023773454 cites W2172257129 @default.
• W2023773454 doi "https://doi.org/10.1016/j.jaad.2011.10.020" @default.
• W2023773454 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22153792" @default.
• W2023773454 hasPublicationYear "2012" @default.
• W2023773454 type Work @default.
• W2023773454 sameAs 2023773454 @default.
• W2023773454 citedByCount "51" @default.
• W2023773454 countsByYear W20237734542013 @default.
• W2023773454 countsByYear W20237734542014 @default.
• W2023773454 countsByYear W20237734542015 @default.
• W2023773454 countsByYear W20237734542016 @default.
• W2023773454 countsByYear W20237734542017 @default.
• W2023773454 countsByYear W20237734542018 @default.
• W2023773454 countsByYear W20237734542019 @default.
• W2023773454 countsByYear W20237734542020 @default.
• W2023773454 countsByYear W20237734542021 @default.
• W2023773454 countsByYear W20237734542022 @default.
• W2023773454 crossrefType "journal-article" @default.
• W2023773454 hasAuthorship W2023773454A5012920754 @default.
• W2023773454 hasAuthorship W2023773454A5018964407 @default.
• W2023773454 hasAuthorship W2023773454A5031806804 @default.
• W2023773454 hasAuthorship W2023773454A5038028069 @default.
• W2023773454 hasAuthorship W2023773454A5049859852 @default.
• W2023773454 hasAuthorship W2023773454A5058395343 @default.
• W2023773454 hasAuthorship W2023773454A5060819284 @default.
• W2023773454 hasAuthorship W2023773454A5061557806 @default.
• W2023773454 hasAuthorship W2023773454A5074434801 @default.
• W2023773454 hasAuthorship W2023773454A5080223253 @default.
• W2023773454 hasAuthorship W2023773454A5080237247 @default.
• W2023773454 hasConcept C126322002 @default.
• W2023773454 hasConcept C141071460 @default.
• W2023773454 hasConcept C16005928 @default.
• W2023773454 hasConcept C168563851 @default.
• W2023773454 hasConcept C17991360 @default.
• W2023773454 hasConcept C188816634 @default.
• W2023773454 hasConcept C197934379 @default.
• W2023773454 hasConcept C203092338 @default.
• W2023773454 hasConcept C2776173921 @default.
• W2023773454 hasConcept C2777011040 @default.
• W2023773454 hasConcept C2777138892 @default.
• W2023773454 hasConcept C2777226972 @default.
• W2023773454 hasConcept C2779384505 @default.
• W2023773454 hasConcept C2780564577 @default.
• W2023773454 hasConcept C44249647 @default.
• W2023773454 hasConcept C71924100 @default.
• W2023773454 hasConcept C90924648 @default.
• W2023773454 hasConceptScore W2023773454C126322002 @default.
• W2023773454 hasConceptScore W2023773454C141071460 @default.
• W2023773454 hasConceptScore W2023773454C16005928 @default.
• W2023773454 hasConceptScore W2023773454C168563851 @default.
• W2023773454 hasConceptScore W2023773454C17991360 @default.
• W2023773454 hasConceptScore W2023773454C188816634 @default.
• W2023773454 hasConceptScore W2023773454C197934379 @default.
• W2023773454 hasConceptScore W2023773454C203092338 @default.
• W2023773454 hasConceptScore W2023773454C2776173921 @default.
• W2023773454 hasConceptScore W2023773454C2777011040 @default.
• W2023773454 hasConceptScore W2023773454C2777138892 @default.
• W2023773454 hasConceptScore W2023773454C2777226972 @default.

• next